STOCK TITAN
  1. Home
  2. News
  3. ABBV

AbbVie to Host First-Quarter 2024 Earnings Conference Call

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
AbbVie (ABBV) to release first-quarter 2024 financial results on April 26, 2024, with a live webcast of the earnings conference call.
Positive
  • None.
Negative
  • None.

NORTH CHICAGO, Ill., April. 4, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its first-quarter 2024 financial results on Friday, April 26, 2024, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

AbbVie logo

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/abbvie-to-host-first-quarter-2024-earnings-conference-call-302107732.html

SOURCE AbbVie

AbbVie (ABBV) will release its first-quarter 2024 financial results on April 26, 2024.

AbbVie (ABBV) will host the live webcast of the earnings conference call at 8 a.m. Central time.

Investors can access the live webcast of AbbVie's (ABBV) earnings conference call through AbbVie's Investor Relations website at investors.abbvie.com.

Yes, an archived edition of the session will be available later on the same day.
Stock ABBV logo
Abbvie Inc

NYSE:ABBV

ABBV Rankings

#30 Ranked by Market Cap
#2312 Ranked by Stock Gains
#886 Ranked by Dividends

ABBV Latest News

Apr 26, 2024
AbbVie Reports First-Quarter 2024 Financial Results
Apr 25, 2024
New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study
Apr 23, 2024
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands
Apr 18, 2024
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis
Apr 12, 2024
AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine

ABBV Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Pharmaceuticals: Major, Manufacturing, Pharmaceutical Preparation Manufacturing
US
North Chicago

About ABBV

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis.